Delivery Order SPE2DB22D2206-SPE2DB25FJS02
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $18,065.90 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion pharmaceutical prime vendor agreement running...
- The Defense Logistics Agency awarded a delivery order valued at $14,182.44 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,943.19 on July 18, 2025, for the supply of Xeljanz XR 11 mg tablets (30-count units). This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $12,570.58, represents a non-competitive, non-set-aside procurement and is scheduled for completion by August 26, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $6,059.18 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed price delivery order is non-set-aside and represents a competitive award to the pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, PA....
- The Defense Logistics Agency awarded a delivery order valued at $18,191.81 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on August 25, 2025, with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a direct fulfillment of pharmaceutical supply needs for federal medical procurement. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $4,343.52 firm fixed price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 29, 2025, with completion targeted for July 30, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $3,914.17 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by August 18, 2025. The delivery order is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $36,826.65 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 5, 2025. This delivery order represents a single...
- The Defense Logistics Agency awarded a delivery order valued at $13,132.00 to AmerisourceBergen Drug Corp for the supply of Xeljanz 10 mg tablets (60-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJS02Delivery Order
The Defense Logistics Agency awarded a $11,611.46 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Xeljanz 5 mg tablets (60-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 29, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime contract vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support mechanism for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, fulfills a vital role in supplying brand-name and generic medications to Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates consistent capability in delivering diverse pharmaceutical products across multiple therapeutic domains through competitive procurement processes. This particular delivery order for Xeljanz, a rheumatoid arthritis treatment, exemplifies the company's role in ensuring pharmaceutical availability for military and federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.6k | 8/28/25 |